2024 Endocrinology Grand Rounds | Type 1 Diabetes Prevention and Disease Modifying Therapies: An Update
Type 1 Diabetes (T1D) is a chronic condition that requires lifelong management. Preventing it could significantly enhance the quality of life for those who would otherwise develop the disease, reducing the burden of daily insulin administration and glucose monitoring. People with T1D are at higher risk for severe complications, including cardiovascular disease, kidney damage, nerve damage, and vision problems. Preventing T1D could decrease the incidence of these complications, reducing healthcare costs and improving overall health outcomes.
There are current gaps in knowledge and practice due to advances in the field that have happened over the last few years. There are various ways researchers are looking into prevention of type 1 DM and there is a need to address their pros and cons. An updated review of the prevention of type 1 DM by various mechanisms including islet cell transplants, immunomodulation, vaccines etc. is imperative. Over the last few years, this field of research has shown enormous progress and there are FDA approved medications to delay onset of type 1 DM. Clinicians must stay abreast of the latest updates in the prevention of type 1 Diabetes mellitus.
Target Audience
Faculty and Staff of department of Diabetes, Endocrinology and Metabolism.
Learning Objectives
- Outline the stages of development of type 1 diabetes mellitus (DM).
- Review genetic/molecular mechanism behind the development of type 1 DM.
- Assess strategies for prevention of type 1 DM.
- Discuss current status and future directions in this field.
Virtual Meeting- Zoom
Alberto Pugliese, MD The Samuel Rahbar Endowed Chair in Diabetes & Drug Discovery; Chair and Professor, Department of Diabetes Immunology; Director, The Wanek Family Project for Type 1 Diabetes, Arthur Riggs Diabetes & Metabolism Research Institute;
City of Hope
Presenter: Dr. Pugliese has indicated that there are no relevant financial relationships.
Planner: Dr. Pooja Manroa has indicated that there are no relevant financial relationships.
This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2024 Endocrinology Grand Rounds | Type 1 Diabetes Prevention and Disease Modifying Therapies: An Update for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance